Last reviewed · How we verify

Corneregel

Laboratorios Sophia S.A de C.V. · Phase 1 active Small molecule ✓ Verified May 2026 Quality 15/100

Corneregel is a Small molecule drug developed by Laboratorios Sophia S.A de C.V.. It is currently in Phase 1 development. Also known as: dexpanthenol.

Corneregel, also known as BAY81-2996, is a topical treatment that has been studied for its potential benefits in wound healing, skin recovery, flu, cold, and allergic disorders of the respiratory system. It is a form of dexpanthenol, a derivative of pantothenic acid, which is a B vitamin.

Likelihood of approval
9.6% vs 9.6% industry baseline
If approved by FDA: likely 2033–2036
Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission
Confidence: Medium
Why this estimate
  • Baseline phase 1 → approval rate +9.6pp
    Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Predicted approval windows by jurisdiction (conditional on FDA approval)
Regulator Country Likely year Lag vs FDA
FDA US 2033–2036
EMA EU 2034–2037 +0.7 yr
MHRA GB 2034–2037 +0.7 yr
Health Canada CA 2034–2038 +0.9 yr
TGA AU 2034–2038 +1.2 yr
PMDA JP 2034–2038 +1.5 yr
NMPA CN 2035–2039 +2.3 yr
MFDS KR 2034–2038 +1.4 yr
CDSCO IN 2034–2039 +1.8 yr
ANVISA BR 2035–2039 +2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic nameCorneregel
Also known asdexpanthenol
SponsorLaboratorios Sophia S.A de C.V.
ModalitySmall molecule
Therapeutic areaOther
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Corneregel

What is Corneregel?

Corneregel is a Small molecule drug developed by Laboratorios Sophia S.A de C.V..

Who makes Corneregel?

Corneregel is developed by Laboratorios Sophia S.A de C.V. (see full Laboratorios Sophia S.A de C.V. pipeline at /company/laboratorios-sophia-s-a-de-c-v).

Is Corneregel also known as anything else?

Corneregel is also known as dexpanthenol.

What development phase is Corneregel in?

Corneregel is in Phase 1.

What are the side effects of Corneregel?

Common side effects of Corneregel include Ocular burning, headache, rhinitis, earache, eyelid bruise, elevated liver enzymes.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing